Drugs /

trastuzumab

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
trastuzumab
Trade Name(s):
Herceptin
NCI Definition [1]:
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for trastuzumab

Trastuzumab has been investigated in 205 clinical trials, of which 146 are open and 59 are closed. Of the trials investigating trastuzumab, 3 are early phase 1 (2 open), 31 are phase 1 (19 open), 28 are phase 1/phase 2 (19 open), 106 are phase 2 (76 open), 3 are phase 2/phase 3 (2 open), 31 are phase 3 (25 open), and 3 are no phase specified (3 open).

ERBB2 Amplification, HER2 Positive, and HER2 Overexpression are the most frequent biomarker inclusion criteria for trastuzumab clinical trials.

Breast carcinoma, adenocarcinoma of the gastroesophageal junction, and gastric adenocarcinoma are the most common diseases being investigated in trastuzumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Trastuzumab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Trastuzumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating trastuzumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
trastuzumab, herceptin biosimilar pf-05280014, trastuzumab, moab her2, anti-c-erb-2, trastuzumab biosimilar abp 980, trastuzumab biosimilar sb3, anti-erbb2 monoclonal antibody, anti-erbb-2, anti her2, 6667, herceptin®, immunoglobulin g 1 (human-mouse monoclonal rhumab her2gamma1-chain antihuman p185(sup c-erbb2) receptor), disulfide with human-mouse monoclonal rhumab her2 light chain, dimer, monoclonal antibody her2, trastuzumab (product), c-erb-2 monoclonal antibody, her2 monoclonal antibody, pf-05280014, trastuzumab biosimilar abp 980, anti-erbb-2, monoclonal antibody c-erb-2, herceptin trastuzumab biosimilar pf-05280014, trastuzumab biosimilar pf-05280014, abp 980, anti-c-erbb2 monoclonal antibody, her2 monoclonal antibody, anti-p185-her2, anti-erb-2, anti-her2/c-erbb2 monoclonal antibody, herceptin biosimilar pf-05280014, 688097, anti-c-erbb2 monoclonal antibody, rhumab her2, ig gamma-1 chain c region, monoclonal antibody her2, moab her2, ro0452317, anti-c-erb-2, anti-erb-2, monoclonal antibody c-erb-2, anti-her2/c-erbb2 monoclonal antibody, anti-erbb2 monoclonal antibody, herceptin trastuzumab biosimilar pf-05280014, trastuzumab biosimilar pf-05280014, Herceptin, trastuzumab [chemical/ingredient], trastuzumab (substance), anti-p185-her2
Drug Categories [2]:
Therapeutic antibodies
Drug Target(s) [2]:
ERBB2
NCIT ID [1]:
C1647
SNOMED ID [1]:
F-61BDA

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.